Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK3 | Q9Y572 | 8/20 | 0.56 |
| ▸ | CSNK1E | P49674 | 9/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3123892 | 0.87 | CSNK1E (0.64) | RIPK3CSNK1EHASPINALDH1A1CYP3A4 | |
| SCHEMBL3719615 | 0.87 | RIPK3 (0.56) | RIPK3CSNK1EKCNH2HDAC1HDAC2 | |
| SCHEMBL13351193 | 0.85 | RIPK3 (0.65) | RIPK3CSNK1EHASPIN | |
| SCHEMBL3119961 | 0.84 | CSNK1E (0.65) | RIPK3CSNK1E | |
| SCHEMBL477090 | 0.82 | CSNK1E (0.70) | RIPK3CSNK1EALDH1A1CYP3A4HPGD | |
| SCHEMBL3121002 | 0.82 | CSNK1E (0.53) | RIPK3CSNK1EHASPINALDH1A1CYP3A4 | |
| SCHEMBL3108614 | 0.80 | CSNK1E (0.61) | RIPK3CSNK1EHASPIN | |
| SCHEMBL3115962 | 0.79 | CSNK1E (0.68) | RIPK3CSNK1EALDH1A1CYP3A4HPGD | |
| SCHEMBL3112007 | 0.78 | CSNK1E (0.67) | RIPK3CSNK1E | |
| SCHEMBL477103 | 0.77 | CSNK1E (0.64) | RIPK3CSNK1EKCNH2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-07-25 | — | — | US | disclosed |
| EP-2398802-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010070237-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | CSNK2A1, CSNK1A1, CSNK2A2 | RIPK3 1086/4885CSNK1E 11/4885KCNH2 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.